PT-141 (bremelanotide) is well-tolerated by most people, but it comes with a predictable set of side effects you should understand before your first injection. Nausea is the most common, affecting roughly 40% of users in Phase III clinical trials. A temporary rise in blood pressure occurs in most patients. Both effects are short-lived and manageable when you go in prepared and have a licensed medical team overseeing your care.
1. What Is PT-141 and Why Does the Safety Profile Matter?
PT-141 (bremelanotide) is a peptide that activates melanocortin receptors in the brain involved in sexual desire and response. The FDA approved it in 2019 as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD), and it is prescribed off-label through licensed telehealth providers for broader libido support in both women and men.
Because PT-141 works through the central nervous system rather than through blood flow, its side effect profile is distinct from other sexual wellness treatments. Most of what you experience happens within the first one to two hours after injection and resolves on its own. Understanding that timeline, and knowing which symptoms warrant a call to your provider, is an important part of starting treatment with confidence.
This guide covers the complete picture: what is common, what is rare, what is serious, and who should not use PT-141. You can learn more about how PT-141 works and what to expect from treatment at our PT-141 overview page and our guide specifically for men.
2. PT-141 Side Effects: The Full Breakdown
Common Side Effects (More Than 10% of Users)
These effects appear in Phase III RECONNECT trials and are documented in the FDA prescribing information for Vyleesi (bremelanotide 1.75 mg subcutaneous injection).
Nausea. Nausea is the most frequently reported side effect, affecting approximately 40% of patients in clinical trials compared to just 1% in the placebo group. It typically begins within 15 to 60 minutes of injection and passes within 2 hours for most people. The first dose tends to produce the strongest reaction, many patients find nausea diminishes with subsequent use as the body adjusts.
Taking an anti-nausea medication such as ondansetron 30 minutes before injection can significantly reduce this effect. Injecting after a light meal may also help. Your Telezen MD provider can discuss whether a preventive dose makes sense for your situation.
Flushing. About 20% of users experience flushing, a warm, reddish sensation in the face, neck, or chest, typically within the first hour after injection. It resolves on its own within 30 to 90 minutes and is uncomfortable but not dangerous for most people.
Injection Site Reactions. Approximately 13% of users report localized reactions at the injection site, including redness, mild bruising, or swelling. Rotating injection sites between uses, alternating between the abdomen and thigh, reduces cumulative irritation. Your Telezen MD provider will review proper injection technique when your medication is dispensed.
Headache. Headache occurs in about 11% of users in clinical trials. It is typically mild and resolves without treatment within a few hours. Staying well-hydrated before and after injection tends to reduce severity.
3. PT-141 Side Effects at a Glance
| Category | Side Effect | Frequency | Typical Duration |
|---|---|---|---|
| Common | Nausea | ~40% | 1-2 hours |
| Common | Flushing | ~20% | 30-90 minutes |
| Common | Injection site reaction | ~13% | Hours to 2 days |
| Common | Headache | ~11% | 1-3 hours |
| Uncommon | Vomiting | ~5% | 1-2 hours |
| Uncommon | Fatigue | ~3% | Hours |
| Uncommon | Hot flashes | ~3% | 30-90 minutes |
| Uncommon | Dizziness | ~2% | Hours |
| Uncommon | Nasal congestion | ~2% | Hours |
| Serious | Transient blood pressure increase | Most users | 8-12 hours |
| Serious (chronic use) | Focal hyperpigmentation | Varies | Persistent |
4. The Blood Pressure Effect: What You Need to Know
The cardiovascular effect of PT-141 is the one that matters most from a safety standpoint, even though most people do not notice it directly.
PT-141 causes a temporary increase in blood pressure in the hours after injection. Phase III trial data and the FDA prescribing information for Vyleesi document the rise as approximately 6 to 8 mmHg systolic and 3 to 4 mmHg diastolic, peaking between 30 minutes and 4 hours post-dose, then returning to baseline within 8 to 12 hours. Heart rate may decrease slightly, up to 5 beats per minute, during the same window.
For healthy individuals with normal, well-controlled blood pressure, this temporary change is clinically acceptable. For people with uncontrolled hypertension, known cardiovascular disease, or a history of heart attack or stroke, this effect is a genuine contraindication. This is why cardiovascular screening before starting PT-141 is not optional, it is part of responsible prescribing, and it is built into the Telezen MD intake process.
5. Hyperpigmentation with Frequent Use
PT-141 activates not only the MC3R and MC4R receptors responsible for its libido effects, but also the MC1R receptor, which plays a role in skin pigmentation. With frequent or high-dose use, some patients notice focal darkening of the skin, particularly near injection sites.
This effect is more common with use exceeding the recommended frequency. Clinical protocols typically limit PT-141 use to no more than once per week. Following the dosing schedule your Telezen MD provider establishes significantly reduces this risk. If you have darker skin or pre-existing hyperpigmentation conditions, discuss this specifically with your provider before you start.
6. Who Should Not Use PT-141
PT-141 is not appropriate for everyone. The Telezen MD intake process screens for these contraindications, but understanding them helps you have a more informed conversation with your medical team.
Uncontrolled High Blood Pressure or Cardiovascular Disease. Because PT-141 causes a temporary rise in blood pressure, anyone with uncontrolled hypertension, a history of cardiovascular events, or significant cardiovascular risk should not use it. If your blood pressure is well-managed with medication and your healthcare provider has cleared you, your Telezen MD team can evaluate your situation on a case-by-case basis.
Pregnancy or Plans to Become Pregnant. PT-141 is contraindicated during pregnancy. Animal studies have suggested potential developmental effects at therapeutic doses. Reliable contraception should be confirmed before starting treatment.
Current Use of Naltrexone. PT-141 slows gastric motility and can reduce absorption of some oral medications taken around the same time. Clinical studies found this was generally not clinically significant, with one exception: naltrexone. If you are taking naltrexone for any reason, report this during your intake before starting PT-141.
Low or Unstable Blood Pressure. Although PT-141 typically raises blood pressure temporarily, patients with conditions involving unpredictable cardiovascular responses should be evaluated carefully before starting. Your intake review is where this assessment happens.
7. How Telezen MD Supports Your Safety
Starting PT-141 at Telezen MD begins with a thorough online medical intake, a real clinical review, not a sales process. You submit your complete health history and current medications, and a licensed medical provider reviews your file within 24 hours. If PT-141 is appropriate for you, they issue a prescription. Your medication is then compounded and shipped from a 503A FDA-regulated pharmacy directly to your door.
The 503A pharmacy designation matters. Compounding pharmacies operating under 503A oversight are regulated at the state and federal level and must meet strict quality standards. What you receive is not research-grade material, it is a clinically prepared, pharmacist-compounded formulation prescribed specifically for you.
Your Telezen MD provider does not disappear after your prescription is issued. If you experience side effects, have questions about dosing, or want to adjust your protocol, the same medical team that reviewed your intake remains available. Concierge-level access means you do not wait for a scheduled follow-up when something comes up.
To learn more about what the process looks like from intake to delivery, visit our PT-141 overview page or our detailed guide for men.
Frequently Asked Questions
What is the most common side effect of PT-141?
Nausea is the most common side effect, affecting roughly 40% of users in Phase III clinical trials compared to 1% in the placebo group. It typically begins within 15 to 60 minutes of injection and passes within 2 hours. Pre-medicating with an anti-nausea medication before injection significantly reduces nausea for most patients. The effect tends to be strongest with the first dose and diminishes over time.
Does PT-141 affect blood pressure?
Yes. PT-141 causes a temporary increase in blood pressure in most users, typically 6 to 8 mmHg systolic, peaking in the first few hours after injection and returning to baseline within 8 to 12 hours. This is why PT-141 is not recommended for people with uncontrolled hypertension or cardiovascular disease. A medical intake that screens for cardiovascular risk is a required first step before starting treatment.
Can PT-141 cause skin darkening?
With frequent or high-dose use, some patients notice focal hyperpigmentation near injection sites. This is related to MC1R activation, a secondary effect of the melanocortin mechanism. With use at the recommended frequency, typically no more than once per week, this risk is significantly lower. Patients with darker complexions or pre-existing hyperpigmentation should discuss this with their provider before starting.
How long do PT-141 side effects last?
Most common side effects resolve quickly. Nausea and flushing typically pass within 1 to 2 hours. Headache usually resolves within a few hours. The temporary blood pressure increase returns to baseline within 8 to 12 hours. Injection site reactions may take 24 to 48 hours to fully clear.
Is it safe to use PT-141 more than once a week?
Clinical protocols typically recommend no more than once per week, even though the FDA-approved label for Vyleesi allows up to once per 24 hours. Staying within the weekly window reduces the risk of focal hyperpigmentation and minimizes cumulative cardiovascular exposure. Your Telezen MD provider will set a dosing frequency appropriate for your situation.
Who should not take PT-141?
People with uncontrolled high blood pressure, known cardiovascular disease, current pregnancy, or who are taking naltrexone should not use PT-141. A thorough medical intake with a licensed provider is the appropriate way to determine whether PT-141 is safe for your specific health profile.
Ready to Start PT-141 with Medical Support Behind You?
Side effects are manageable when you go in prepared and have a licensed medical team that stays involved. At Telezen MD, your provider reviews your complete health history before your prescription is issued, your medication arrives from a 503A FDA-regulated compounding pharmacy, and the same medical team remains accessible throughout your treatment.
Visit our PT-141 overview page to learn more about how the program works, or explore our detailed guide for men. Complete your intake online and have a licensed provider review your file within 24 hours.
Sources
- U.S. Food and Drug Administration. Vyleesi (bremelanotide injection) prescribing information. NDA 210557. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
- Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908. https://pubmed.ncbi.nlm.nih.gov/31599840/
- Clayton AH, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol. 2019;134(5):909-917. https://pmc.ncbi.nlm.nih.gov/articles/PMC6819023/
- Simon JA, et al. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectr. 2022;27(1):61-68. https://pubmed.ncbi.nlm.nih.gov/33455598/
Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Telezen MD services are available only to patients who qualify following an online medical evaluation with a licensed healthcare provider. Results vary by individual. Compounded medications prescribed through Telezen MD are compounded by 503A FDA-regulated pharmacies. Compounded medications are not reviewed or approved by the FDA for safety or efficacy. Statements on this page have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any new medical treatment. If you experience any adverse effects, contact your provider immediately.
